Moreover, we propose the zidovudine and gemcitabine co-treatment may be a novel therapeutic strategy for pancreatic cancer by targeting the gemcitabine-induced EMT-like phenotype and suppression of hENT1 expression. This evidence concerns the gene SLC29A1 and familial pancreatic carcinoma.